1887

Journal of General Virology header logo

Volume 98, Issue 7

Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies Free

Abstract

We investigated naturally occurring variation within the major (L1) and minor (L2) capsid proteins of human papillomavirus (HPV) genotype 33. Pseudoviruses (PsV) representing HPV33 lineages A1, A2, A3, B and C exhibited comparable particle-to-infectivity ratios and morphology but demonstrated a decreased sensitivity (A2, A3, B and C) to cross-neutralization by HPV vaccine antibodies compared to the A1 sublineage. Chimeric PsVs demonstrated that these differences in sensitivity were due to polymorphisms in the L1 protein, with little or no influence from variation within the L2 protein. Site-directed mutagenesis of the L1 gene identified the DE loop residue 133 and the FG residue 266 as being critical for conferring this differential sensitivity. The use of HPV33 homology models based upon the HPV16 crystal structure suggested that they are likely to act independently on more than one antibody epitope. These data improve our understanding of the potential impact of natural capsid variation on recognition by vaccine antibodies.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antibody , human papillomavirus , L1 , L2 , lineage , neutralization , vaccine and variant
© 2017 The material produced by Public Health England is crown copyright
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000829
2017-07-01
2024-05-06
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/7/1755.html?itemId=/content/journal/jgv/10.1099/jgv.0.000829&mimeType=html&fmt=ahah

References

  1. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30:F12–F23 [View Article][PubMed]
     [Google Scholar]
  2. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008; 9:267–276 [View Article][PubMed]
     [Google Scholar]
  3. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology 2013; 445:232–243 [View Article][PubMed]
     [Google Scholar]
  4. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B et al. A review of human carcinogens—Part B: biological agents. Lancet Oncol 2009; 10:321–322 [View Article][PubMed]
     [Google Scholar]
  5. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048–1056 [View Article][PubMed]
     [Google Scholar]
  6. Chen Z, Schiffman M, Herrero R, Desalle R, Anastos K et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011; 6:e20183 [View Article][PubMed]
     [Google Scholar]
  7. Chen AA, Heideman DA, Boon D, Chen Z, Burk RD et al. Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. Virology 2014; 448:356–362 [View Article][PubMed]
     [Google Scholar]
  8. Xi LF, Schiffman M, Koutsky LA, Hughes JP, Winer RL et al. Lineages of oncogenic human papillomavirus types other than type 16 and 18 and risk for cervical intraepithelial neoplasia. J Natl Cancer Inst 2014; 106: [View Article][PubMed]
     [Google Scholar]
  9. Xi LF, Schiffman M, Koutsky LA, Hughes JP, Hulbert A et al. Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia. Int J Cancer 2016; 139:1098–1105 [View Article][PubMed]
     [Google Scholar]
  10. Buck CB, Day PM, Trus BL. The papillomavirus major capsid protein L1. Virology 2013; 445:169–174 [View Article][PubMed]
     [Google Scholar]
  11. Wang JW, Roden RB. L2, the minor capsid protein of papillomavirus. Virology 2013; 445:175–186 [View Article][PubMed]
     [Google Scholar]
  12. Guan J, Bywaters SM, Brendle SA, Ashley RE, Makhov AM et al. Cryoelectron microscopy maps of human papillomavirus 16 reveal L2 densities and heparin binding site. Structure 2017; 25:253–263 [View Article][PubMed]
     [Google Scholar]
  13. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012; 10:681–692 [View Article][PubMed]
     [Google Scholar]
  14. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013; 10:400–410 [View Article][PubMed]
     [Google Scholar]
  15. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959–3963[PubMed]
     [Google Scholar]
  16. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92:11553–11557 [View Article][PubMed]
     [Google Scholar]
  17. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 2011; 85:13253–13259 [View Article][PubMed]
     [Google Scholar]
  18. Malagón T, Drolet M, Boily MC, Franco EL, Jit M et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781–789 [View Article][PubMed]
     [Google Scholar]
  19. Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G et al. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 2011; 29:8585–8590 [View Article][PubMed]
     [Google Scholar]
  20. Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K et al. A randomized, observer-blinded immunogenicity trial of Cervarix® and Gardasil® Human papillomavirus vaccines in 12-15 year old girls. PLoS One 2013; 8:e61825 [View Article][PubMed]
     [Google Scholar]
  21. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359–1373 [View Article][PubMed]
     [Google Scholar]
  22. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011; 29:2011–2014 [View Article][PubMed]
     [Google Scholar]
  23. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000; 5:557–567 [View Article][PubMed]
     [Google Scholar]
  24. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007; 282:31803–31811 [View Article][PubMed]
     [Google Scholar]
  25. Ahmed AI, Bissett SL, Beddows S. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect Genet Evol 2013; 18:151–159 [View Article][PubMed]
     [Google Scholar]
  26. Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 2001; 279:361–369 [View Article][PubMed]
     [Google Scholar]
  27. Bissett SL, Godi A, Fleury MJ, Touze A, Cocuzza C et al. Naturally occurring capsid protein variants of human papillomavirus genotype 31 represent a single L1 serotype. J Virol 2015; 89:7748–7757 [View Article][PubMed]
     [Google Scholar]
  28. Godi A, Facchetti A, Bissett SL, Cocuzza C, Miller E et al. Naturally occurring major and minor capsid protein variants of human papillomavirus 45 (HPV45): differential recognition by cross-neutralizing antibodies generated by HPV vaccines. J Virol 2015; 90:3247–3252 [View Article][PubMed]
     [Google Scholar]
  29. Guan J, Bywaters SM, Brendle SA, Lee H, Ashley RE et al. Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virology 2015; 483:253–263 [View Article][PubMed]
     [Google Scholar]
  30. Guan J, Bywaters SM, Brendle SA, Lee H, Ashley RE et al. The U4 antibody epitope on human papillomavirus 16 identified by cryo-electron microscopy. J Virol 2015; 89:12108–12117 [View Article][PubMed]
     [Google Scholar]
  31. Lee H, Brendle SA, Bywaters SM, Guan J, Ashley RE et al. A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment. J Virol 2015; 89:1428–1438 [View Article][PubMed]
     [Google Scholar]
  32. Roth SD, Sapp M, Streeck RE, Selinka HC. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virol J 2006; 3:83 [View Article][PubMed]
     [Google Scholar]
  33. Bissett SL, Godi A, Beddows S. The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies. Sci Rep 2016; 6:39730 [View Article][PubMed]
     [Google Scholar]
  34. Krajden M, Cook D, Yu A, Chow R, Su Q et al. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 2014; 32:624–630 [View Article][PubMed]
     [Google Scholar]
  35. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205–216 [View Article][PubMed]
     [Google Scholar]
  36. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7:1343–1358 [View Article][PubMed]
     [Google Scholar]
  37. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L et al. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol 2013; 87:6062–6072 [View Article][PubMed]
     [Google Scholar]
  38. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711–723 [View Article][PubMed]
     [Google Scholar]
  39. Herrero R, González P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015; 16:e206e216 [View Article][PubMed]
     [Google Scholar]
  40. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016; 4:e453e463 [View Article][PubMed]
     [Google Scholar]
  41. Bissett SL, Wilkinson D, Tettmar KI, Jones N, Stanford E et al. Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology. Clin Vaccine Immunol 2012; 19:449–451 [View Article][PubMed]
     [Google Scholar]
  42. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003; 31:3381–3385 [View Article][PubMed]
     [Google Scholar]
  43. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J et al. Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc 2009; 4:1–13 [View Article][PubMed]
     [Google Scholar]
  44. Benkert P, Biasini M, Schwede T. Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics 2011; 27:343–350 [View Article][PubMed]
     [Google Scholar]
  45. Siqueira JD, Alves BM, Prellwitz IM, Furtado C, Meyrelles ÂR et al. Identification of novel human papillomavirus lineages and sublineages in HIV/HPV-coinfected pregnant women by next-generation sequencing. Virology 2016; 493:202–208 [View Article][PubMed]
     [Google Scholar]
  46. Wu X, Zhang C, Feng S, Liu C, Li Y et al. Detection of HPV types and neutralizing antibodies in Gansu province, China. J Med Virol 2009; 81:693–702 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000829
Loading
Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies
J. Gen. Virol. 98, 1755 (2017); https://doi.org/10.1099/jgv.0.000829
/content/journal/jgv/10.1099/jgv.0.000829
/content/journal/jgv/10.1099/jgv.0.000829
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error